Connection

ANITA DESWAL to Drug Administration Schedule

This is a "connection" page, showing publications ANITA DESWAL has written about Drug Administration Schedule.
Connection Strength

0.259
  1. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol Clin. 2008 Feb; 26(1):1-14, v.
    View in: PubMed
    Score: 0.061
  2. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007 Jul 03; 50(1):32-6.
    View in: PubMed
    Score: 0.058
  3. Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. Heart Fail Clin. 2005 Apr; 1(1):25-37.
    View in: PubMed
    Score: 0.049
  4. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29; 99(25):3224-6.
    View in: PubMed
    Score: 0.033
  5. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012 Nov; 164(5):763-770.e3.
    View in: PubMed
    Score: 0.021
  6. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 03; 364(9):797-805.
    View in: PubMed
    Score: 0.019
  7. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag. 2010 Aug 09; 6:449-55.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.